[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345826-105":59,"doc-detail-345826-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","tp53-mutation-is-associated-with-shorter-treatment-duration-with-cdk46-inhibitors-but-not-with-immune-checkpoint-inhibitors-in-er-positiveher2-negative-breast-cancer-real-world-perspective","TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer - real-world perspective","","TP53 mutation is a critical driver of breast cancer, yet its impact on treatment outcomes remains unclear. This study examines real-world associations between TP53 mutation and response to CDK4/6 inhibitors and immune checkpoint inhibitors in ER-positive/HER2-negative disease using METABRIC and the C-CAT cohort from Japan. Treatment duration is used as a surrogate for exposure and potential benefit, with results evaluated across age groups.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tp53-mutation-is-associated-with-shorter-treatment-duration-with-cdk46-inhibitors-but-not-with-immune-checkpoint-inhibitors-in-er-positiveher2-negative-breast-cancer-real-world-perspective/345826/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tp53-mutation-is-associated-with-shorter-treatment-duration-with-cdk46-inhibitors-but-not-with-immune-checkpoint-inhibitors-in-er-positiveher2-negative-breast-cancer-real-world-perspective/345826.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about TP53 mutation in breast cancer?","Question",{"text":112,"@type":113},"The study evaluates whether TP53 mutation is associated with differences in treatment duration for CDK4/6 inhibitors and immune checkpoint inhibitors in ER-positive/HER2-negative breast cancer, using real-world data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is treatment duration used in this research?",{"text":117,"@type":113},"Treatment duration serves as a real-world surrogate endpoint reflecting treatment exposure and potential clinical benefit.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main findings regarding CDK4/6 inhibitors and immune checkpoint inhibitors?",{"text":121,"@type":113},"TP53 mutations are linked to shorter CDK4/6 inhibitor treatment duration (with similar trends for abemaciclib and palbociclib), while TP53 mutations are not associated with ICI treatment duration.",{"name":123,"@type":110,"acceptedAnswer":124},"How does age affect the relationship between TP53 mutation and treatment duration?",{"text":125,"@type":113},"Patients in the AYA group have the shortest treatment duration, with TP53 prevalence decreasing with age. In age-stratified analyses, TP53 mutation is associated with shorter treatment duration in perimenopausal, menopausal, and older groups, but not in the AYA group; formal interaction testing does not show a significant interaction with age group.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345826,1790438633,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Oshi etal. Breast Cancer Research (2026) 28:130 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02305-9](https://doi.org/10.1186/s13058-026-02305-9)  \nRESEARCH Open Access  \nTP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective  \nMasanori Oshi1,2*, Makoto Sugimori3, Kei Kawashima 1,2, Shipra Gandhi4, Akimitsu Yamada2, Kazutaka Narui5, Takashi Ishikawa6, Itaru Endo2 and Kazuaki Takabe1,2,6  \nAbstract  \nBackground TP53 mutation is a critical driver of breast cancer, yet its relationship with treatment outcomes for breast cancer remains unclear. This study investigates the association between TP53 mutation and response to CDK4/6 inhibitors (CDK4/6i) and immune checkpoint inhibitors (ICI) in breast cancer using real-world data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort, focusing on age-related differences.  \nMethods METABRIC (n = 1355) was used for initial survival analysis, and gene set enrichment analysis (GSEA) was performed to identify pathways enriched inTP53-mutated ER-positive/HER2-negative breast cancers. Clinical and genomic data of metastatic breast cancer (mBC) patients in Japan were analyzed in the C-CAT (n = 1668) cohort. Treatment duration was used as a real-world surrogate endpoint reflecting treatment exposure and potential clinical benefit. Patients were stratified by age into four groups: Adolescents and Young Adults (AYA; 15–39 years), perimenopausal (40–54 years), menopausal (55–64 years), and older (≥ 65 years) .  \nResults TP53 mutations were associated with poor prognosis in the METABRIC cohort. GSEA showed TP53-mutated tumors were enriched with gene sets related to cell proliferation and immune response, while TP53 wild-type tumors enriched for estrogen response pathways. In the C-CAT cohort, TP53 mutations were linked to shorter CDK4/6i treatment duration with similar trends observed for both abemaciclib and palbociclib. However, TP53 mutations were not associated with ICI treatment duration. Patients in the AYA group had the shortest treatment duration, with TP53 mutation prevalence decreasing with age. In age-stratified analyses, TP53 mutation was associated with shorter treatment duration in perimenopausal, menopausal, and older groups but not in the AYA group. However, formal interaction testing did not detect a significant interaction between TP53 mutation and age group.  \n*Correspondence:  \nMasanori Oshi[oshi. mas.wc@yokohama-cu.ac.jp](oshi. mas.wc@yokohama-cu.ac.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nOshi et al. Breast Cancer Research (2026) 28:130 Page 2 of 13  \nConclusion TP53 mutation is associated with shorter CDK4/6i treatment duration, highlighting","cbCaimSXgxNIOsJZ","https://ap.wps.com/l/cbCaimSXgxNIOsJZ","pdf",1988792,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Clinical context and rationale\n## Evidence on TP53 and treatment resistance","[{\"question\":\"What question does the study address about TP53 mutation in breast cancer?\",\"answer\":\"The study evaluates whether TP53 mutation is associated with differences in treatment duration for CDK4/6 inhibitors and immune checkpoint inhibitors in ER-positive/HER2-negative breast cancer, using real-world data.\"},{\"question\":\"How is treatment duration used in this research?\",\"answer\":\"Treatment duration serves as a real-world surrogate endpoint reflecting treatment exposure and potential clinical benefit.\"},{\"question\":\"What are the main findings regarding CDK4/6 inhibitors and immune checkpoint inhibitors?\",\"answer\":\"TP53 mutations are linked to shorter CDK4/6 inhibitor treatment duration (with similar trends for abemaciclib and palbociclib), while TP53 mutations are not associated with ICI treatment duration.\"},{\"question\":\"How does age affect the relationship between TP53 mutation and treatment duration?\",\"answer\":\"Patients in the AYA group have the shortest treatment duration, with TP53 prevalence decreasing with age. In age-stratified analyses, TP53 mutation is associated with shorter treatment duration in perimenopausal, menopausal, and older groups, but not in the AYA group; formal interaction testing does not show a significant interaction with age group.\"}]","TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer - real-world perspective | PDF",1790059021,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f94f033e3f5da02a9d4f7abb9ac68c9.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95d5cba811026a741519fbcce52cebb6.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9e2f82c57d12331d426ee3d78a39ed7.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72fd901e37c345644d30ee46244694ff.webp",980,1306]